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Abstract: The underlying cellular mechanisms that characterize aging are complex and 
multifaceted. However, it is emerging that aging could be regulated by two distinct metabolic 
hubs. These hubs are the pathway defined by the mammalian target of rapamycin (mTOR) 
and that defined by the NAD+-dependent deacetylase enzyme, SIRT1. Recent experimental 
evidence suggests that there is crosstalk between these two important pathways; however, 
the mechanisms underpinning their interaction(s) remains poorly understood. In this review, 
we propose using computational modelling in tandem with experimentation to delineate the 
mechanism(s). We briefly discuss the main modelling frameworks that could be used to 
disentangle this relationship and present a reduced reaction pathway that could be modelled. 
We conclude by outlining the limitations of computational modelling and by discussing 
opportunities for future progress in this area. 
Keywords: aging; computational modelling; mammalian target of rapamycin; systems 
biology; simulation; sirtuins; SIRT1; regulatory network 
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1. Introduction 
One of the great challenges in biology is to understand the underlying mechanisms of aging. Aging 
is recognized as a deleterious process that occurs during the lifespan of an organism, gradually rendering 
it increasingly vulnerable to mortality [1]. Aging is characterized by its complexity and that it affects all 
aspects of biology, from molecular processes to the whole organism. Cells are the essential building 
blocks of the human body; therefore, it is logical that mammalian cellular decline underpins the aging 
process. Over the years, several cellular mechanisms have been suggested as the underlying cause of 
aging. For example, cellular senescence, a phenomenon that occurs when normal differentiating cells 
stop dividing, was widely regarded as a viable model of aging [2,3]. However, it became apparent that 
senescence can accompany a diverse range of other cellular events. For instance, Harley et al. (1990) 
revealed that telomere shortening is associated with cellular senescence [4], and in certain cell lines, 
cells can even cause senescence (reviewed in [5]). In addition, mitochondria have been long recognized 
as a source of cellular damage, due to the deleterious consequences of reactive oxidative species (ROS) 
escaping from the mitochondrial electron transport chain during cellular respiration [6–8]. ROS can 
compromise the integrity of the cell by damaging lipids, proteins and nuclear/mitochondrial DNA [9]. 
For this reason, the production of ROS has been associated with telomere dysfunction [10] and cellular 
senescence, demonstrating the intertwined nature of aging [11,12]. Crosstalk among a variety of other 
cellular activities has also been implicated in how aging unfolds [13–15]. Thus, a general consensus has 
evolved that mammalian aging is not dictated by a single cellular event operating in isolation; it is the 
result of the interplay of a diverse range of biological processes operating over a wide-range of spatial 
and temporal scales. As a result of these findings, it has been recognized that in order to gain a more 
complete understanding of the mechanics of aging, integration of multiple biological pathways need to 
be considered [16,17]. For example, Passos et al. (2010) used in silico interactome analysis and live cell 
microscopy to show the presence of a dynamic feedback loop between p21 and cellular ROS levels [11]. 
Regardless of the approach that is adopted, a better understanding of aging is especially important 
due to an increase in age-related pathologies, such as cardiovascular disease (CVD) [18]. The aim of the 
systems biology paradigm is to provide an integrated interpretation and understanding of fundamental 
biological processes from the molecular through to the physiological [19–23]. Central to the systems 
biology approach is computational modelling, which involves using mathematics to quantitatively 
represent the dynamics of biological systems. Recently, computational models have been utilized  
to investigate the dynamics of aging, making it possible to intuitively represent the detailed  
networks of genes, proteins, metabolites and biochemical reactions that characterize this complex  
phenomenon [24–27]. A worthwhile resource for sourcing aging data at these different biological levels 
is the recently developed Digital Ageing Atlas (DAA) [28]. This is a freely accessible online database 
that has been designed specifically for archiving age-related data at various levels [28]. Within the dense 
biological circuitry that underpins aging, several important metabolic hubs are suggested to regulate 
longevity and health span. These include pathways defined by the mammalian target of rapamycin 
(mTOR) [29] and that defined by the NAD+-dependent deacetylase enzyme, SIRT1 [30]. mTOR and 
SIRT1 are involved in coordinating the availability of nutrients and energy to a wide range of cellular 
functions. Figure 1 presents a coarse-grained network diagram of these pathways, their interaction as 
proposed by Ghosh et al. (2010) and the cellular processes they impact [31]. It is possible that the 
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intensity of the metabolic current passing through Figure 1 is modulated by caloric restriction (CR), a 
dietary regime that involves reducing nutrient intake without causing malnutrition [32,33]. This dietary 
regime has been shown to extend lifespan in a diverse range of organisms, and it is generally accepted 
that the effects of CR are at least partly mediated via these key metabolic pathways [34,35]. However, 
it must be stressed at this point that this is very much an open question, and it remains to be fully 
established if there is a link between CR and SIRT1 (recently reviewed in [36]). Despite this uncertainty, 
the relationship(s) between the mTOR and SIRT1 pathways have been the subject of intense scrutiny 
due to the potential they may offer for extending health span via pharmacological interventions that 
could replicate the effects of CR [37,38]. However, it remains unclear how their interplay might 
contribute to longevity. In this article, we explore mTOR and SIRT1 as metabolic sensors and the major 
pathways that they regulate. Experimental investigations that have examined their crosstalk will be 
discussed and a case presented for computationally modelling their interplay. A framework that could 
be used to do this will be outlined, and we will also define the challenges and opportunities that could 
influence how computational modelling is used in the future to investigate aging. 
 
Figure 1. A coarse-grained overview of the metabolic pathways regulated by mTOR and 
SIRT1. The figure also shows SIRT1 inhibiting mTOR, as suggested by Ghosh et al. (2010). 
2. mTOR and Aging 
mTOR is a serine/threonine protein kinase of the phosphatidylinositol-3-OH kinase (PI(3)K)-related 
family [39]. It acts as a key metabolic sensor in a wide range of biological effects, both at a cellular and 
organism level [40]. This ability to act as a regulator causes it to respond to an array of both intrinsic 
and extrinsic cellular signals. These signals include genotoxic stress, oxygen levels and hormone/nutrient 
levels [41–43]. mTOR forms the catalytic subunit of two discrete signaling complexes, known as  
mTOR complexes 1 and 2 (mTORC1 and mTORC2). In response to intracellular and extracellular cues, 
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the mTOR pathway impacts cell growth and proliferation by stimulating anabolic processes, including 
biosynthesis of proteins, lipids and organelles, and by restricting catabolic processes, such as  
autophagy [44]. As a result, mTOR has been recognized as a key metabolic hub that can influence cell 
growth and survival [45]. Thus, it is logical to assume that mTOR could be a master metabolic controller 
with the potential to regulate both aging and the pathologies of old age. It is thus not surprising that 
recent efforts have focused on applying inhibitors of this pathway to the study of healthy aging [46].  
For instance, evidence from mouse models suggests that inhibition of mTOR rescues cognitive 
deterioration, which is a clinical manifestation of Alzheimer’s disease [47–49]. Moreover, sporadic 
mutation or dysregulation of protein kinase B and the tuberous sclerosis complex, which are upstream 
components of the mTOR pathway, are frequently altered in cancer [50–52]. Another function of  
mTOR that has been associated with cancer development is tumour angiogenesis [53]. The mTOR  
kinase inhibitor rapamycin, also known as sirolimus, is an antifungal agent produced by the bacteria 
Streptomyces hygroscopicus and has long been touted as a therapeutic target of cancer [54,55].  
For example, analogues of rapamycin have historically been used as chemotherapeutic agents against 
solid tumour types [56], including breast cancer [57,58]. Rapamycin has anti-angiogenesis effects, which 
are suggested to be mediated by lowering vascular endothelial growth factor (VEGF), a downstream 
product of the mTOR1 complex [59]. It could be very tentatively suggested, therefore, that over-activated 
mTOR promotes cancer growth by augmenting the supply of VEGF. 
Rapamycin fed late in life has also been show to extend lifespan in genetically heterogeneous  
mice [60]. However, an alternative, more recent study has shown that, although rapamycin can extend 
lifespan in mice, it did not improve healthy aging [61]. Rapamycin, however, had similar effects on 
young animals, indicating that the effects of rapamycin were not due to a modulation of aging, but rather 
related to aging-independent drug effects. The life-extending effects of CR could, in part, be due to 
inhibition of mTOR, as suggested by the findings in Drosophila [62] and yeast [63]. CR has been shown 
to activate 4E-BP1 in Drosophila, resulting in increased translation of macromolecules involved in the 
mitochondrial electron transport chain and associated lifespan extension [64]. This increased 
functionality could be due to a reduction in ROS damage, as it has been suggested that inhibition of 
mTORC1 by rapamycin lowers mitochondrial membrane potential, oxygen consumption and cellular 
ATP levels [65,66], and it has been found that rapamycin inhibition can dramatically alter mitochondrial 
phosphoproteome [65]. It has been observed that mitochondrial DNA copy number, as well as the 
expression of several genes encoding proteins involved in oxidative metabolism are reduced by 
rapamycin and increased by mutations that activate mTORC1 signaling [66]. 
3. Metabolic Crosstalk between mTOR and SIRT1 
Silent information regulator proteins, otherwise known as sirtuins (SIRTUINS), are an evolutionarily 
group of enzymes that operate as NAD+-dependent deacetylases [67]. There are seven known 
mammalian sirtuins that are localized to various parts of the cell [68]. Sirtuins take part in a diverse 
range of cellular activities, from nutrient sensing [68] to DNA damage/repair [69]. The response of 
sirtuins to environmental factors, as well as their potential role in aging is unclear. What is known is that 
SIRT1, the most extensively studied of the sirtuins, regulates various metabolic processes, which enable 
the cell to adapt to nutrient perturbations. In response to fasting, for example, SIRT1 modulates 
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gluconeogenesis in the liver [70]. Moreover, SIRT1 has various other functions, including the regulation 
of fat mobilization; the control of glucose stimulated insulin secretion; and the mediation of stress 
responses [71]. It has also been implicated in cardiovascular function, where it is suggested to play a 
protective role in preventing cardiac hypertrophy [72]. Several recent studies have suggested that there 
is a link between these two metabolic networks. For example, Hong et al. (2014) showed that  
acetylation of a region needed to maintain the activity of p70 ribosomal S6 kinase (S6K1) blocks its 
mTORC1-dependent Thr-389 phosphorylation [73]. Thr-389 is a key phosphorylation site needed to 
maintain S6K1 activity. Acetylation of S6K1 is inhibited by SIRT1 and SIRT2, suggesting that sirtuin 
regulated acetylation of S6K1 is needed for mTORC1-dependent S6K1 activation [73]. Moreover, it was 
demonstrated by Ghosh and colleagues using both mouse and human cells that SIRT1 interacts with 
TSC2, a component of the mTOR inhibitory-complex upstream to mTORC1 and regulates mTOR 
signaling in a TSC2-dependent manner. These results suggested that SIRT1 negatively regulates mTOR 
signaling potentially through the TSC1/2 complex [31]. Guo et al. (2011) reported similar findings in 
mice with enhanced neuronal SIRT1 expression. This was accompanied by inhibition of mTOR 
downstream signaling activity (decreased p70S6 kinase (p70S6K) phosphorylation at Thr389). 
Interestingly, the authors suggest that Sirt1 may act to promote the growth and survival of neurons in 
the central nervous system via negatively regulating mTOR signaling [74]. 
4. Therapeutic Avenues for Treating Age-Related Disease? 
It has been suggested for some time that the mTOR and SIRT1 signaling pathways play a vital role 
in the onset and progression of aging and age-related diseases. However, some of the findings 
surrounding these pathways suggest that a number of possible paradoxes are present in their involvement 
in aging. mTOR, as has been previously mentioned, is a key cellular regulator of anabolic processes and 
autophagy. The decreased muscle mass evident from aging would suggest that an upregulation of this 
signaling pathway would therefore be beneficial. Bodine et al. (2001) found that activation of the 
Akt/mTOR pathway could induce muscular hypertrophy and reduced atrophy in disused limbs in both 
rats and mice [75]. For those suffering from sarcopenia or age-related muscular atrophy, this could 
provide a significant step in improving quality of life in later years. The decrease in growth hormone 
(GH) and insulin-like growth factor (IGF) concentrations that occur with age would suggest that 
administration could counter the progression of osteoporosis, sarcopenia and even CVD [76]. IGF-1 has 
been shown to up-regulate the Akt/mTOR pathway and, therefore, to increase protein synthesis [77]. 
However, an attenuated insulin/IGF-1 signaling has been shown to extend lifespan whilst mutations in 
IGF-1 receptors in humans have been linked to increased longevity. The interaction of GH and IGF 
signaling and their effect on aging/longevity have been examined in a number of studies using mice. 
These have demonstrated that a GH deficiency or a deletion of GH receptors can significantly reduce 
the effect of aging and increase longevity [76]. As IGF-1 mediates the effects of GH, it has been 
suggested that it is actually the IGF signaling pathway that is in some way responsible for intensifying 
the aging process [76]. Once again, in mice with low circulating levels of IGF-1 or with a deletion of  
the IGF-1 receptors, an increase in longevity in females, but not males, has been found [76]. Rapamycin, 
is now regularly used as an immunosuppressant to help prevent organ rejection after transplants. Recent 
data have demonstrated that rapamycin is associated with significantly extending lifespan in mice [78], 
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and it is through the inhibition of the mTOR signaling pathway that it is proposed to exert its effect [79]. 
Of further interest is the fact that the timing of administration of rapamycin appears to influence its 
impact. Miller et al. (2011) found that administration in mice at nine months (equivalent to ~20 years 
old in a human) provided no additional benefit compared to those given rapamycin at 20 months 
(equivalent to ~60 years old in a human) [80]. This suggests that there would not necessarily be a need 
for lifelong supplementation of rapamycin in order to extend health span, should the same benefit be 
found in humans. 
A further substance that has been strongly linked with the possibility of increasing health span is 
resveratrol, a plant polyphenol found in grape skins and some other food sources, that has been suggested 
to mimic calorie restriction [81]. Despite some positive evidence suggesting resveratrol can improve 
glucose and lipid metabolism, the role this polyphenol plays in cancer and cardiovascular disease 
progression remains to be fully elucidated [82]. Recent findings have suggested that resveratrol can 
suppress cellular senescence in human cells; however, this was limited by its toxicity, which occurs at 
higher concentrations [83]. In contrast, a review by Cottart et al. (2014) found that it was relatively well 
tolerated at doses above 0.5 g/day over long periods [82]. It has been suggested that resveratrol inhibits 
mTOR signaling pathways by increasing the association between mTOR and its inhibitor DEPTOR, 
thereby limiting the downstream signaling of mTOR [84]. In addition, an increased expression of SIRT1 
has also been postulated as another mechanism by which resveratrol can exert its effect [85]. An increase 
in SIRT1 could help to reduce oxidative stress, thereby reducing cell damage and ultimately slowing 
down the aging process. Whilst there have been some positive findings with regards to supplementation 
strategies that may help to slow down the aging process, there is still some way to go before these 
methods can be definitively said to improve/limit the process of aging. In summary, both rapamycin and 
resveratrol have shown some positive effects in various animal models; however, there is a much 
stronger argument for rapamycin being a candidate for extending health span (reviewed in [36]). 
However, there is still some debate as to the level of impact possible and if the positive effects observed 
in a mouse model will truly transfer to the human level [82]. 
5. Mathematical Approaches to Modelling of Biological Pathways 
The exact mechanisms that underpin the interaction between SIRT1 and mTOR remain to be 
discovered. Unravelling their relationship is hampered by the complexity of the pathways that they 
regulate. Therefore, a full understanding of their interconnectivity is difficult to envisage in the near 
future. Consequently, we propose breaking the interactions into well-characterized regulatory circuits 
with mTOR and SIRT1 hubs within the circuits, then using computational modelling in conjunction with 
experimentation to gain a deeper mechanistic understanding of their interactivity. To do this, it is 
important to appreciate how to construct a mathematical model of a biological pathway, as several 
approaches can be employed. Here, we briefly discuss some of the approaches that have commonly been 
used in systems biology and give examples of where they have been applied to aging studies. We also 
briefly highlight the advantages and disadvantages of using these approaches. 
One important method that has been successfully applied to metabolic networks is flux balance 
analysis (FBA). In this approach, each intermediate metabolite pool is assumed to be in a steady state. 
This defines a set of mass balance constraints that must be satisfied by any feasible flux pattern and that 
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can be solved efficiently for large, even genome-scale models, to understand global interactions [86]. 
Figure 2 provides a simple pathway to illustrate the concept. Metabolite B, for example, is produced by 
flux 𝝂 
𝟏
 and consumed by fluxes 𝝂 
𝟐
 and 𝝂 
𝟑
. If the concentration of B is assumed not to vary over time, 
its rate of change (first derivative with respect to time) can be set to zero, which implies the following 
simple relationship between these fluxes: 𝝂 
𝟏
− 𝝂 
𝟐
− 𝝂 
𝟑
= 𝟎. A similar analysis of Metabolite C gives 
another constraint: 𝝂 
𝟐
− 𝝂 
𝟒
= 𝟎 . For larger networks, the balancing of hundreds or thousands of 
metabolites gives the same number of constraints that the fluxes must satisfy. This “constraint space” 
can be efficiently searched by mathematical optimization algorithms to find a flux pattern that optimizes 
a certain objective, such as maximization of the cell growth rate. FBA has been widely used to interpret 
metabolic data, for example in a study on the effect of aging on key metabolite fluxes in hypoxia 
tolerance in Drosophila [87]. Although originally devised for steady-state metabolic networks, these 
methods have found some limited application for dynamic signaling networks of the type considered 
here [88] and also gene regulation [89]. From an aging perspective, several other models are worth 
mentioning; for example, the FBA model of mitochondrial energy metabolism by Ramakrishna and 
colleagues [90]. This model was used to characterize the optimal flux distributions for maximal ATP 
production in the mitochondrion. The model predicted the expected ATP yields for glucose, lactate and 
palmitate alongside the secretion of TCA-cycle intermediates, which is observed during mitochondrial 
disease [90]. More recently, Nogiec and colleagues (2015) used FBA modelling to create a  
systems-level model of insulin resistance, under a variety of nutrient conditions. The metabolic network 
was probed to isolate reactions that replicate the clinical manifestations of an insulin resistance-linked 
metabolic state [91]. Yizhak et al. (2013) also focused on the area of healthy ageing and generated a 
metabolic transformation algorithm [92]. This algorithm has the goal of identifying health states within 
a metabolic network that has been perturbed by disease. According to the authors, the algorithm was 
able to predict novel drug targets for human ageing based on analyses of several genes associated with 
lifespan extension in yeast. In terms of disadvantages, flux models are not based on mechanistic 
biochemical kinetics; therefore, they are limited at predicting metabolic conditions. This means that 
although the “transportation infrastructure” of the cell is quite well characterized by FBA, the kinetic rates, 
information exchange and regulation that control the flow of molecules around these metabolic networks 
are far less well understood. They are also solely based on model steady states, and fluxes are inferred 
based on steady states. This is not a true reflection of reality, as regulatory processes are inherently dynamic 
in nature and, therefore, require an alternative dynamic or time-dependent modelling approach [93]. 
The most ubiquitous approach for dynamic modelling of biological pathways involves the second 
class of computational models discussed here, namely dynamic deterministic simulations using ordinary 
differential equations (ODEs). In these models, the state variables of the system can be metabolites  
or anything in which the concentration is dynamically altered over time by reactions that produce or 
consume them. These reactions can be enzyme-catalysed transformations of metabolites, post-translational 
modifications of proteins or synthesis reactions, such as transcription and translation. Unlike FBA 
models, ODE models require some mechanistic understanding of the reactions involved, as well as 
estimates of the associated kinetic parameters. This requirement for parameter values limits the size of 
ODE models, even more than computational tractability. The typical ODE model size is a few reactions 
or a few tens of reactions for larger models, whereas FBA models frequently approach the so-called 
“genome scale” of a few hundred or several thousand reactions. The goal of deterministic ODE models 
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is to encapsulate the dynamics of the system by capturing the behaviour of reaction velocities. Several 
recent excellent ODE models have been applied to the understanding of aging. For example, a recent 
mathematical model by Kowald et al. (2012) was used in conjunction with experimental analysis of 
Podospora anserina strains in which the mitochondrial superoxide dismutase, PaSOD3, was enhanced [94]. 
This combined approach was able to indicate that superoxide may not be the primary ROS responsible 
for age-related molecular decline, which has significant ramifications for the free radical theory of  
aging [6,8]. Another worthwhile recent model by Proctor et al. (2014) utilized an ODE approach and 
stochastic methods (see below) to assess the therapeutic intervention points for the prevention of  
age-related cytokine-induced cartilage breakdown. The model predicted that simulated inhibition of  
c-Jun N-terminal kinase or p38 mitogen-activated protein kinases and overexpression of tissue  
inhibitor of metalloproteinases 3 (TIMP-3) led to a reduction in collagen release [95]. One of the 
disadvantages associated with using this approach is parameter uncertainty. This presents a challenge 
for developing reliable ODE models of biological pathways. Some recent methods to address this issue 
are discussed in Sections 6 and 7. Further disadvantages include the fact that ODE models are often 
based on the assumption of spatial homogeneity, and thus, the challenge of incorporating widely 
different timescales needs to be overcome. This implicitly assumes that a considerable number of 
molecules take part in the reactions and that the average behaviour of the population of molecules is not 
affected by individual heterogeneity. This assumption may not be valid for certain signaling proteins 
and transcripts that have low copy numbers per cell, and this may require the use of stochastic models. 
Therefore, the final approach that will be discussed briefly is stochastic modelling. This type of model 
is used if there is variability within the biological system [96]. A stochastic simulator can be utilized if 
a small number of molecules are suggested to be involved in discrete random collisions within a 
biochemical/molecular pathway. Computationally, this approach involves an algorithm treating each 
reaction in the model as a probability function, e.g., biochemical reactions have different probabilities 
of taking place, which can be altered depending on the nature of the reaction [97–99]. There is now 
considerable experimental evidence to support the application of this framework to a broad range of 
biological processes [100,101]. It is recognized that stochasticity contributes to aging [102]; thus, it is 
important to consider this for any future model of mTOR and SIRT1 interplay. Recently stochastic 
models have been used to represent cellular oxidative damage [103], telomere shortening [104], heat 
shock protein homeostasis [105] and a variety of biochemical pathways involved in the aging process. 
The disadvantages of stochastic modelling mainly centre on the fact that, in the main computational 
systems biology, researchers tend to rely heavily on the Gillespie algorithm or one of its variants (a 
statistically exact method). Although simple to use and intuitive to understand, this method is extremely 
computationally intensive, as it must simulate every single reaction [98,99,106]. 
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Figure 2. A simple pathway illustrating a metabolic flux model. 
6. Resources for Model Assembly 
Assembling a model of a metabolic network or a signaling pathway using the reaction-based approach 
requires a number of things. Firstly, it is important to establish if the model has been assembled before. 
This may involve consulting a database, such a BioModels [107], that archives models that have been 
encoded in the model exchange format systems biology mark-up language (SBML) [108]. It also 
requires detailed knowledge of the metabolic reactions and their patterns of interaction. This reaction 
list can be converted into to a network diagram that explicitly outlines the nature of the reactions. This 
is more formal that a biological diagram of the system and aims to represent the network in a very precise 
manner. There are a number of ways of creating a network diagram. Recently, systems biology graphical 
notation has been suggested as a standardized method for generating network diagrams [109]. Reaction 
modelling also requires detailed knowledge of each reaction and their mechanisms. This often depends 
on the availability of kinetic data, which can be obtained from databases, such as the BRaunschweig 
ENzyme DAtabase (BRENDA) [110],  the System for the Analysis of Biochemical Pathways - Reaction 
Kinetics (SABIO-RK) [111] or BioNumbers [112]. If kinetic data are available, but the values are 
different, as they have been obtained using a wide variety of experimental conditions, then it is necessary 
to build this uncertainty into the model. Uncertain kinetic values can be considered in the modelling 
process using a sensitivity analysis, which investigates the relationship between uncertain model inputs 
and the resulting variation in the model outputs. Information on the reactions can also be derived from 
wet-laboratory observations of time-course behaviour. These data are necessary in order to infer a 
reasonable parameter set to establish the validity of the model. This is important, as the utility of the 
model is dependent to a large extent on how complete the knowledge is of the metabolic system. A 
software tool is also necessary for model building. It is now unnecessary to have an advanced 
understanding of mathematics and computer programming, as significant progress has been made 
recently and there is a plethora of freely available modelling tools that are intuitive and reasonably 
straightforward to use (reviewed in [113]). Many software tools are capable of running simulations of 
the metabolic network model and also have built-in features that allow modellers to conduct sensitivity 
analysis or parameter estimation. 
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7. Current Limitations and Future Developments 
There a number of issues that can impede the development of a model in this area. Firstly, a large 
number of biological systems remain poorly understood mechanistically. This makes an integrated 
mathematical description of their mechanisms inherently challenging. Moreover, this problem feeds 
forward into parameter selection; if the mechanisms have not been fully delineated, then it is probable 
that there will be a paucity of measurements with which to infer accurate parameter values. A variety of 
techniques have been developed for estimating parameters that are not identifiable in the strict mathematical 
sense [114,115]. Residual parameter uncertainty, however, has an impact on model extension, because 
if the parameters of the original model are unclear, this raises questions over the value of extending the 
model further. This is particularly frustrating from the perspective of the aging process as, due to its 
intrinsic complexity, holistic models are a necessity if we are to improve our understanding of this 
process. To help overcome these difficulties, Kriete et al. (2010) created a noteworthy rule-based cell 
systems model of aging that included the mTOR pathway along with several other pathways related to 
aging [116]. This semi-quantitative model enabled the authors to represent aging in a holistic fashion 
that was defined by connectivity/rules among all components involved. Another promising direction for 
future research is the development of algorithmic methods for reducing model complexity and 
identifying, from the ensemble of uncertain model parameters, the critical components that demand 
further investigation. A good example of this is sensitivity analysis to determine those parameters that 
exert the most influence over a particular model output [117]. The performance of formal techniques for 
automated model reduction of systems biology models has also been studied by Dokoumetzidis and 
Aarons [118]. Recently, Rao and colleagues (2014) developed a model reduction method for biochemical 
reaction networks [119]. The method employed a stepwise reduction in the number of complexes, 
defined as the left- and right-hand sides of the reactions in the network. The reduced network has fewer 
complexes, reactions, variables and parameters when compared to the original network, and yet, the 
behaviour of a preselected set of significant metabolites in the reduced network closely resembles that 
of the original network. Moreover, the reduced network largely retains the structure and kinetics of the 
original model. A yeast model of glycolysis was reduced from 12 to seven variables. This reduction was 
able to improve the understanding of the dynamics of the network and presents a means of facilitating 
model parameterization or to embed a detailed model of interest in a more coarse-grained, yet realistic 
environment [120]. This type of approach could be important for modelling the interaction between 
mTOR and SIRT1, because their metabolic activities comprise a multitude of relationships that 
encapsulates the dynamic behaviour between enzymes, metabolites and cofactors. Given the current 
limited understanding of the mechanisms that underpin these pathways and the cloudiness surrounding 
their interactivity, constructing a detailed model of their circuitry is to a large extent futile. Rather, it is 
vital that computational models are informed by recent experimental evidence and that they are used to 
test a particular idea or hypothesis relating to a component or components of a reasonably well-defined 
system. The incorporation of model entities needs to be informed by metabolic circuitry that has been at 
least partly characterized experimentally. As an example, we created a diagram that could be used as a 
starting point to model the interaction of mTOR and SIRT1 (Figure 3). This diagram is informed by the 
hypothesis outlined by Ghosh et al. (2010) [31], in which the authors suggest SIRT1 negatively regulates 
mTOR signaling through inhibition of the TSC1/2 complex. Our idea centres on capturing this effect 
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together with the key components of this pathway. The next step would be to code our putative model 
using a software tool, such as CellDesigner [121] or Copasi [122], both of which have been designed to 
support the SBML exchange framework, which would facilitate model updating. It would then be 
necessary to parameterize the model. Following this, simulations could be conducted along with a 
sensitivity analysis. The model could then be ultimately used to explore the relationship between mTOR 
and SIRT1 based on current experimental knowledge. 
 
Figure 3. Proposed reduced model of SIRT1 and mTOR interaction based on Ghosh et al. 
(2010) [31]. Insulin binds to IRs resulting in autophosphorylation. IRs can be phosphorylated 
or unphosphorylated [123]. The active IR induces the phosphorylation of IRS-1 via the 
activity of protein tyrosine kinase. This signal depends on phosphorylated IR. IRS1p docks 
with PI3-kinase. This results in the formation of the IRS-1/activated PI3-kinase complex 
(IRS1pPI3). Dissociation of the complex is dependent on IRS1pPI3. Phosphorylation of Akt 
depends on IRS1pPI3 and is reversible. Formation of the TSC1/2 complex depends on 
phosphorylated Akt. The TS1/2 complex inhibits the conversion of inactive Rheb to active 
Rheb (Rheb-GTP). RhebA activates mTORC1. Activation of mTORC1 affects S6K, while 
the activity of S6K is triggered by phosphorylation [124]. The activity of S6 kinase triggers 
feedback mechanisms inhibiting IRS-1. mTORp provokes cell metabolism and growth. We 
explore the proposed interaction between mTOR and SIRT1 by having SIRT1 bind with the 
TSC1/2 complex to inhibit active Rheb formation. Thus, the SIRT1 TSC1/2 complex 
association is included as an inhibitor of active Rheb formation and subsequent mTOR 
signaling, as suggested by Ghosh and colleagues. 
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8. Conclusions 
Western populations are gradually aging. With this demographic shift comes a concomitant increase 
in the prevalence of age related-disease. Thus, there is an urgent need to better understand the 
mechanisms that underpin aging. In this article, two metabolic pathways have been proposed as 
fundamental to the progress of aging and age-related disease. The importance of these pathways is 
emphasized by their effects on a diverse range of cellular and metabolic processes. Both pathways are 
modulated by CR, and recent evidence suggests that there is significant crosstalk between these two 
metabolic hubs. However, the precise mechanisms that underpin their interactions remain unclear. One 
way to establish a more complete understanding of the interactions between mTOR and SIRT1 is to use 
mechanistic computational modelling. There are a number of approaches that can be utilized to describe 
the proposed mechanistic interplay between these two metabolic circuits. In general, computational 
models are based on reactions and utilize ordinary differential equations, with the concentrations of 
metabolic entities and parameters inferred from continuous deterministic data to replicate the behaviour 
of the systems. The major limitation of this approach is that it depends on an adequate parameter set 
being inferred from the experimental data. Presently, this is a challenge, as a full kinetic description of 
these pathways has yet to be established. In this paper, we propose that computational modelling focus 
on the experimentally well-understood region within the complex circuitry of these metabolic networks. 
Therefore, we propose that a well-characterized experimental region of a larger circuit is modelled 
initially to gain a firm understanding of its mechanisms. This is a process that is cyclical in nature and 
involves hypothesis generation followed by the gathering of experimental evidence to gradually unravel 
the mechanisms that underpin the metabolic circuitry. Once delineated, these pathways may lead to new 
therapeutic avenues that could increase health span or even delay aging. 
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